Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for psoriasis sufferers: drug targets Hard-to-Treat areas

NCT ID NCT05969223

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug risankizumab (Skyrizi) in 214 adults with moderate to severe genital or scalp psoriasis. Participants received either the drug or a placebo for 16 weeks, then all received the drug. The goal was to see if it could clear or nearly clear the skin in these sensitive areas. The trial is complete, and results will show how safe and effective the treatment is.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

214 people

The number who actually took part.

Started

Aug 2023

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must have clinical diagnosis of chronic plaque psoriasis with or without psoriatic arthritis for at least 6 months before the baseline visit. * Must have a current diagnosis of moderate to severe genital psoriasis (Study-G) defined as static Physician Global Assessment of Genitalia (sPGA-G) ≥ 3 or moderate to severe scalp psoriasis (Study-S) defined as Psoriasis Scalp Severity Index (PSSI) \>= 12, scalp Investigator Global Assessment (IGA) \>= 3, and \>= 30% of the scalp affected. * Must have body surface area (BSA) ≥ 1% with at least 60% of subjects having BSA ≥ 10%; sPGA ≥ 3; inadequate control of psoriasis and/or intolerance to topical treatment, phototherapy and/or systemic therapy; and be candidates for systemic therapy or phototherapy as assessed by the investigator. Exclusion Criteria: * Had previous exposure to IL-23 inhibitors including but not limited to guselkumab, tildrakizumab, ustekinumab, mirikizumab, or risankizumab. * History of an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class. * Non-plaque forms of psoriasis or other active skin disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Genital psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Genital psoriasis Scalp psoriasis

Contacts and locations

Locations

  • Alliance Dermatology and Mohs Center /ID# 255846

    Phoenix, Arizona, 85032, United States

  • Apex Clinical Research Center /ID# 263432

    Mayfield Heights, Ohio, 44124, United States

  • Arlington Dermatology /ID# 255330

    Rolling Meadows, Illinois, 60008, United States

  • Banner University Medicine Dermatology /ID# 255845

    Tucson, Arizona, 85718-1407, United States

  • Care Access - Danville /ID# 266300

    Danville, Virginia, 24541, United States

  • Care Access - Hoboken /ID# 264066

    Hoboken, New Jersey, 07030, United States

  • Center for Clinical Studies - Houston (Binz) /ID# 255396

    Houston, Texas, 77004-8097, United States

  • Center for Clinical Studies Webster TX /ID# 255518

    Webster, Texas, 77598, United States

  • Center for Excellence in Dermatology /ID# 264647

    Kennewick, Washington, 99336, United States

  • Clinical Trials Research Institute /ID# 264555

    Thousand Oaks, California, 91320-2130, United States

  • Darst Dermatology /ID# 255848

    Charlotte, North Carolina, 28277, United States

  • DeNova Research /ID# 264063

    Chicago, Illinois, 60610, United States

  • DermAssociates - Rockville /ID# 263252

    Rockville, Maryland, 20850, United States

  • Dermatology Partners of Leawood /ID# 263244

    Leawood, Kansas, 66211, United States

  • Dermatology Research Associates /ID# 255347

    Los Angeles, California, 90045, United States

  • Florida Academic Dermatology Center /ID# 264065

    Coral Gables, Florida, 33134-5755, United States

  • Forest Hills Dermatology Group @ Union Turnpike /ID# 255346

    Kew Gardens, New York, 11415, United States

  • GSI Clinical Research, LLC /ID# 255472

    Margate, Florida, 33063, United States

  • Hamilton Research, LLC /ID# 255409

    Alpharetta, Georgia, 30022, United States

  • Medical Dermatology Specialists /ID# 262915

    Phoenix, Arizona, 85006, United States

  • Modern Research Associates /ID# 263234

    Dallas, Texas, 75231, United States

  • North Sound Dermatology /ID# 264565

    Mill Creek, Washington, 98012, United States

  • Oregon Dermatology and Research Center /ID# 255670

    Portland, Oregon, 97210, United States

  • Oregon Medical Research Center /ID# 255332

    Portland, Oregon, 97239, United States

  • Private Practice - Dr. Tooraj Raoof /ID# 255334

    Encino, California, 91436, United States

  • Progressive Clinical Research - San Antonio /ID# 263255

    San Antonio, Texas, 78229, United States

  • Renstar Medical Research /ID# 255339

    Ocala, Florida, 34470, United States

  • Schweiger Dermatology, P.C. /ID# 255336

    New York, New York, 07044-2946, United States

  • Skin Cancer and Dermatology Institute (SCDI) /ID# 264570

    Sparks, Nevada, 89436, United States

  • Skin Care Research - Hollywood /ID# 255394

    Hollywood, Florida, 33021-6748, United States

  • Skin Specialists /ID# 262929

    Omaha, Nebraska, 68144, United States

  • Skin and Cancer Associates, LLP /ID# 255506

    Miami, Florida, 33137-3254, United States

  • Studies in Dermatology LLC /ID# 262989

    Cypress, Texas, 77429, United States

  • Sullivan Dermatology /ID# 264067

    Miami, Florida, 33162, United States

  • The Indiana Clinical Trials Center /ID# 255333

    Plainfield, Indiana, 46168, United States

  • Treasure Valley Medical Research /ID# 255671

    Boise, Idaho, 83706, United States

  • U.S. Dermatology Partners Longview /ID# 266325

    Longview, Texas, 75601, United States

  • Wright State Physicians Health Center /ID# 255395

    Fairborn, Ohio, 45324, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.